Patent Issued for Compounds and methods for treating viral infections (USPTO 11730723).
In: Medical Letter on the CDC & FDA, 2023-09-17, S. 1470-1470
serialPeriodical
Zugriff:
Keywords: Biopharmaceutical Companies; Business; COVID-19; Clathrin; Coronaviridae; Coronavirus; Enzymes and Coenzymes; Healthcare Biotechnology Companies; Kinase; Lexicon Pharmaceuticals Inc.; Membrane Proteins; Nidovirales; RNA Viruses; Risk and Prevention; SARS-CoV-2; Severe Acute Respiratory Syndrome Coronavirus 2; Vesicular Transport Proteins; Viral; Virology EN Biopharmaceutical Companies Business COVID-19 Clathrin Coronaviridae Coronavirus Enzymes and Coenzymes Healthcare Biotechnology Companies Kinase Lexicon Pharmaceuticals Inc. Membrane Proteins Nidovirales RNA Viruses Risk and Prevention SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2 Vesicular Transport Proteins Viral Virology 1470 1470 1 09/11/23 20230917 NES 230917 2023 SEP 17 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- Lexicon Pharmaceuticals Inc. (The Woodlands, Texas, United States) has been issued patent number 11730723, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. In some embodiments, the coronavirus is severe acute respiratory syndrome coronavirus (SARS-CoV). The outbreak of severe acute respiratory syndrome (SARS) in 2003, Middle-East respiratory syndrome (MERS) and, more recently, coronavirus disease 2019 (COVID-19) has demonstrated the lethality of CoVs when they cross the species barrier and infect humans. [Extracted from the article]
Copyright of Medical Letter on the CDC & FDA is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Compounds and methods for treating viral infections (USPTO 11730723).
|
---|---|
Zeitschrift: | Medical Letter on the CDC & FDA, 2023-09-17, S. 1470-1470 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1532-4648 (print) |
Sonstiges: |
|